Two-year outcomes of high bleeding risk patients after polymer-free drug-coated stents
J. Am. Coll. Cardiol
; 69(2): 162-171, 2017. graf, tab
Article
em En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1063749
Biblioteca responsável:
BR79.1
ABSTRACT
BACKGROUND:
A 1-year follow-up, polymer-free metallic stent coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective than a bare-metal stent (BMS) for patients with high risk of bleeding.OBJECTIVES:
This study analyzed 2-year outcomes to determine whether these benefits are maintained.METHODS:
In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk patients to receive a drug-coated stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy. The primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis. The primary efficacy endpoint was clinically driven target lesion revascularization.RESULTS:
At 2 years, the primary safety endpoint had occurred in 147 DCS and 180 BMS patients (15.3%) (hazard ratio 0.80; 95% confidence interval 0.64 to 0.99; p = 0.039). Clinically driven target lesion revascularization occurred for 77 DCS and 136 BMS patients (12.0%) (hazard ratio 0.54; 95% confidence interval 0.41 to 0.72; p < 0.0001). Major bleeding occurred in 8.9% of DCS and 9.2% of BMS patients (p = 0.95), and a coronary thrombotic event (myocardial infarction and/or stent thrombosis) occurred in 8.2% of DCS and 10.6% of BMS patients (p = 0.045)...
Buscar no Google
Bases de dados:
CONASS
/
SES-SP
Assunto principal:
Trombose
/
Stents
/
Stents Farmacológicos
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J. Am. Coll. Cardiol
Ano de publicação:
2017
Tipo de documento:
Article